sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.
|
aspirin
|
fenoprofen
|
MECHANISM
|
Fenoprofen_ddi.xml
|
DDI-DrugBank.d154.s0
|
DDI-DrugBank.d154.s0.p0
|
In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL alone (0%).
|
ENBREL
|
anakinra
|
EFFECT
|
Etanercept_ddi.xml
|
DDI-DrugBank.d341.s2
|
DDI-DrugBank.d341.s2.p0
|
Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
|
sucralfate
|
norfloxacin
|
ADVISE
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s11
|
DDI-DrugBank.d217.s11.p18
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
doxycycline
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p14
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
phenytoin
|
doxycycline
|
EFFECT
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p4
|
Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
|
aluminum
|
VIDEX
|
EFFECT
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s4
|
DDI-DrugBank.d43.s4.p12
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
clofibrate
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p12
|
Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).
|
dorzolamide
|
carbonic anhydrase inhibitors
|
EFFECT
|
Dorzolamide_ddi.xml
|
DDI-DrugBank.d34.s0
|
DDI-DrugBank.d34.s0.p0
|
The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.
|
gliftor
|
(-)-erythro-fluorocitrate
|
NONE
|
11170315.xml
|
DDI-MedLine.d125.s0
|
DDI-MedLine.d125.s0.p1
|
However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
|
clozapine
|
fluoxetine
|
MECHANISM
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s22
|
DDI-DrugBank.d480.s22.p5
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
ergot derivatives
|
alprazolam
|
NONE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p112
|
Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylureas
|
salicylates
|
EFFECT
|
Glipizide_ddi.xml
|
DDI-DrugBank.d225.s0
|
DDI-DrugBank.d225.s0.p2
|
Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.
|
Propantheline
|
digoxin
|
MECHANISM
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s5
|
DDI-DrugBank.d450.s5.p1
|
The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
|
ketamine
|
Innovar
|
NONE
|
1167743.xml
|
DDI-MedLine.d23.s0
|
DDI-MedLine.d23.s0.p0
|
When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.
|
anticoagulants
|
FLOLAN
|
EFFECT
|
Epoprostenol_ddi.xml
|
DDI-DrugBank.d241.s1
|
DDI-DrugBank.d241.s1.p2
|
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
|
apomorphine
|
ondansetron
|
EFFECT
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s0
|
DDI-DrugBank.d357.s0.p9
|
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.
|
rifampin
|
corticosteroids
|
MECHANISM
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s18
|
DDI-DrugBank.d314.s18.p12
|
Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.
|
ketoconazole
|
cinacalcet
|
MECHANISM
|
Cinacalcet_ddi.xml
|
DDI-DrugBank.d512.s6
|
DDI-DrugBank.d512.s6.p0
|
To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM).
|
arginine
|
theophylline
|
NONE
|
1116650.xml
|
DDI-MedLine.d74.s2
|
DDI-MedLine.d74.s2.p1
|
Quinolones have been shown to interfere with the metabolism of caffeine.
|
Quinolones
|
caffeine
|
MECHANISM
|
Nalidixic Acid_ddi.xml
|
DDI-DrugBank.d427.s3
|
DDI-DrugBank.d427.s3.p0
|
Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.
|
rifabutin
|
VIRACEPT
|
MECHANISM
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s30
|
DDI-DrugBank.d340.s30.p4
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
bupropion
|
antidepressants
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p0
|
Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.
|
MONUROL
|
metoclopramide
|
MECHANISM
|
Fosfomycin_ddi.xml
|
DDI-DrugBank.d199.s0
|
DDI-DrugBank.d199.s0.p3
|
In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.
|
warfarin
|
warfarin
|
NONE
|
Irbesartan_ddi.xml
|
DDI-DrugBank.d27.s4
|
DDI-DrugBank.d27.s4.p3
|
In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous iloprost and either nifedipine, diltiazem, or captopril.
|
nifedipine
|
captopril
|
NONE
|
Iloprost_ddi.xml
|
DDI-DrugBank.d549.s0
|
DDI-DrugBank.d549.s0.p4
|
Auranofin should be avoided by patients with a history of serious reaction to any gold medication, including Solganal and Myochrysine.
|
Auranofin
|
gold medication
|
ADVISE
|
Auranofin_ddi.xml
|
DDI-DrugBank.d374.s0
|
DDI-DrugBank.d374.s0.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
influenza virus vaccine
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p23
|
The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
|
imipramine
|
fluoxetine
|
MECHANISM
|
Imipramine_ddi.xml
|
DDI-DrugBank.d77.s5
|
DDI-DrugBank.d77.s5.p1
|
Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.
|
nifedipine
|
nifedipine
|
NONE
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s25
|
DDI-DrugBank.d198.s25.p5
|
Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.
|
calcium
|
EMCYT
|
MECHANISM
|
Estramustine_ddi.xml
|
DDI-DrugBank.d481.s0
|
DDI-DrugBank.d481.s0.p0
|
Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.
|
bupropion
|
amantadine
|
EFFECT
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s20
|
DDI-DrugBank.d5.s20.p8
|
Potential drug interactions between Keppra and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
|
phenytoin
|
levetiracetam
|
NONE
|
Levetiracetam_ddi.xml
|
DDI-DrugBank.d212.s11
|
DDI-DrugBank.d212.s11.p47
|
Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).
|
Skeletal muscle relaxants
|
skeletal muscle relaxants
|
NONE
|
Amphotericin B_ddi.xml
|
DDI-DrugBank.d318.s12
|
DDI-DrugBank.d318.s12.p1
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
atorvastatin
|
didanosine
|
NONE
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p17
|
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.
|
ergotamine
|
AXERT
|
ADVISE
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s1
|
DDI-DrugBank.d299.s1.p3
|
Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.
|
Warfarin
|
fluvoxamine maleate
|
NONE
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s30
|
DDI-DrugBank.d76.s30.p0
|
Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.
|
digoxin
|
conivaptan
|
MECHANISM
|
Conivaptan_ddi.xml
|
DDI-DrugBank.d315.s0
|
DDI-DrugBank.d315.s0.p3
|
Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .
|
nateglinide
|
glyburide
|
NONE
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s12
|
DDI-DrugBank.d460.s12.p1
|
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.
|
Fenfluramine
|
methyldopa
|
EFFECT
|
Fenfluramine_ddi.xml
|
DDI-DrugBank.d104.s0
|
DDI-DrugBank.d104.s0.p2
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
disopyramide
|
alprazolam
|
NONE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p42
|
This time window is different than for other oral formulations of ciprofloxacin, which are usually administered 2 hours before or 6 hours after antacids.
|
ciprofloxacin
|
antacids
|
ADVISE
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s10
|
DDI-DrugBank.d123.s10.p0
|
Other CNS depressant drugs should be used with caution in patients taking fenfluramine, since the effects may be additive.
|
CNS depressant drugs
|
fenfluramine
|
ADVISE
|
Fenfluramine_ddi.xml
|
DDI-DrugBank.d104.s1
|
DDI-DrugBank.d104.s1.p0
|
Antacids: Enteric Coated Aspirin should not be given concurrently with antacids, since an increase in the pH of the stomach may effect the enteric coating of the tablets.
|
Aspirin
|
antacids
|
ADVISE
|
Aspirin_ddi.xml
|
DDI-DrugBank.d443.s9
|
DDI-DrugBank.d443.s9.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anesthetics
|
naproxen
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1057
|
Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with DIFFERIN Gel.
|
sulfur
|
salicylic acid
|
NONE
|
Adapalene_ddi.xml
|
DDI-DrugBank.d370.s1
|
DDI-DrugBank.d370.s1.p1
|
Cimetidine: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).
|
Albendazole sulfoxide
|
cimetidine
|
MECHANISM
|
Albendazole_ddi.xml
|
DDI-DrugBank.d321.s4
|
DDI-DrugBank.d321.s4.p3
|
Meperidine: Amphetamines potentiate the analgesic effect of meperidine.
|
Amphetamines
|
meperidine
|
EFFECT
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s16
|
DDI-DrugBank.d158.s16.p2
|
Lithium: generally should not be given with diuretics.
|
Lithium
|
diuretics
|
ADVISE
|
Hydrochlorothiazide_ddi.xml
|
DDI-DrugBank.d162.s9
|
DDI-DrugBank.d162.s9.p0
|
Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
|
nondepolarizing neuromuscular blocking agents
|
phenytoin
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s13
|
DDI-DrugBank.d60.s13.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
bromelains
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p6
|
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
|
aspirin
|
anticoagulants
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s90
|
DDI-DrugBank.d64.s90.p12
|
The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.
|
amantadine
|
benzodiazepines
|
NONE
|
Dicyclomine_ddi.xml
|
DDI-DrugBank.d543.s0
|
DDI-DrugBank.d543.s0.p12
|
Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.
|
Fluvoxamine
|
diazepam
|
ADVISE
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s19
|
DDI-DrugBank.d76.s19.p2
|
Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
|
phenylbutazone
|
aspirin
|
EFFECT
|
Aspirin_ddi.xml
|
DDI-DrugBank.d443.s3
|
DDI-DrugBank.d443.s3.p6
|
Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.
|
loratadine
|
descarboethoxyloratadine
|
NONE
|
Loratadine_ddi.xml
|
DDI-DrugBank.d258.s1
|
DDI-DrugBank.d258.s1.p0
|
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite.
|
18-MC
|
ibogaine
|
NONE
|
11085336.xml
|
DDI-MedLine.d110.s15
|
DDI-MedLine.d110.s15.p0
|
Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.
|
fluvoxamine
|
alprazolam
|
INT
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s10
|
DDI-DrugBank.d76.s10.p2
|
Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.
|
quinolone antibiotics
|
calcium
|
MECHANISM
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s12
|
DDI-DrugBank.d43.s12.p2
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
lithium
|
anesthetics
|
NONE
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p114
|
HEMABATE may augment the activity of other oxytocic agents.
|
HEMABATE
|
oxytocic agents
|
EFFECT
|
Carboprost Tromethamine_ddi.xml
|
DDI-DrugBank.d23.s0
|
DDI-DrugBank.d23.s0.p0
|
Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
|
Cholestyramine
|
thyroxine
|
MECHANISM
|
Cholestyramine_ddi.xml
|
DDI-DrugBank.d566.s0
|
DDI-DrugBank.d566.s0.p8
|
Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
|
methylxanthines
|
adrenergic agonists
|
EFFECT
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s3
|
DDI-DrugBank.d284.s3.p4
|
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or
|
nandrolone
|
oxandrolone
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s3
|
DDI-DrugBank.d179.s3.p9
|
Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.
|
nadolol
|
guanfacine
|
EFFECT
|
Guanfacine_ddi.xml
|
DDI-DrugBank.d507.s5
|
DDI-DrugBank.d507.s5.p4
|
Patients taking disopyramide phosphate and erythromycin concomitantly may develop increased serum concentrations of disopyramide resulting in excessive widening of the QRS complex and/or prolongation of the Q-T interval.
|
disopyramide phosphate
|
erythromycin
|
MECHANISM
|
Disopyramide_ddi.xml
|
DDI-DrugBank.d506.s7
|
DDI-DrugBank.d506.s7.p0
|
When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.
|
amiodarone
|
flecainide
|
MECHANISM
|
Flecainide_ddi.xml
|
DDI-DrugBank.d87.s15
|
DDI-DrugBank.d87.s15.p0
|
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
|
VISTIDE
|
tobramycin
|
ADVISE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s3
|
DDI-DrugBank.d260.s3.p1
|
Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
|
choline salicylate
|
bismuth subsalicylate
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s1
|
DDI-DrugBank.d521.s1.p66
|
The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine.
|
azithromycin
|
zidovudine
|
NONE
|
11210404.xml
|
DDI-MedLine.d105.s3
|
DDI-MedLine.d105.s3.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
chymotrypsin
|
methyldopa
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p511
|
Combinations of clindamycin and gentamicin were indifferent for 16 and synergistic for 11 of the resistant strains.
|
clindamycin
|
gentamicin
|
EFFECT
|
15825309.xml
|
DDI-MedLine.d49.s8
|
DDI-MedLine.d49.s8.p0
|
Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.
|
phenytoin
|
exemestane
|
MECHANISM
|
Exemestane_ddi.xml
|
DDI-DrugBank.d435.s2
|
DDI-DrugBank.d435.s2.p6
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
valproate
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p23
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
Chlorotrianisene
|
cyclosporine
|
INT
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p7
|
Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.
|
aluminum
|
Ibandronate
|
MECHANISM
|
Ibandronate_ddi.xml
|
DDI-DrugBank.d440.s1
|
DDI-DrugBank.d440.s1.p6
|
There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.
|
erythromycin
|
anticoagulants
|
EFFECT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s3
|
DDI-DrugBank.d397.s3.p0
|
Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.
|
verapamil
|
Adenocard
|
EFFECT
|
Adenosine_ddi.xml
|
DDI-DrugBank.d226.s1
|
DDI-DrugBank.d226.s1.p2
|
Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
|
retinoids
|
acitretin
|
ADVISE
|
Acitretin_ddi.xml
|
DDI-DrugBank.d353.s12
|
DDI-DrugBank.d353.s12.p9
|
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
|
Benzthiazide
|
decongestant drugs
|
INT
|
Benzthiazide_ddi.xml
|
DDI-DrugBank.d208.s0
|
DDI-DrugBank.d208.s0.p2
|
However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
|
quinolones
|
caffeine
|
MECHANISM
|
Levofloxacin_ddi.xml
|
DDI-DrugBank.d242.s1
|
DDI-DrugBank.d242.s1.p1
|
Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
|
epinephrine
|
tricyclic antidepressants
|
ADVISE
|
Imipramine_ddi.xml
|
DDI-DrugBank.d77.s2
|
DDI-DrugBank.d77.s2.p13
|
Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
|
benzodiazepine class
|
phenothiazines classes of antipsychotic agents
|
EFFECT
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s7
|
DDI-DrugBank.d333.s7.p5
|
Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances.
|
Cevimeline
|
beta adrenergic antagonists
|
ADVISE
|
Cevimeline_ddi.xml
|
DDI-DrugBank.d287.s0
|
DDI-DrugBank.d287.s0.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
lorazepam
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p23
|
Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.
|
dirithromycin
|
H 2 -receptor antagonists
|
MECHANISM
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s15
|
DDI-DrugBank.d522.s15.p10
|
Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.
|
Cardiac glycosides
|
bepridil hydrochloride
|
EFFECT
|
Bepridil_ddi.xml
|
DDI-DrugBank.d137.s11
|
DDI-DrugBank.d137.s11.p0
|
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
|
Tagamet
|
propranolol
|
MECHANISM
|
Cimetidine_ddi.xml
|
DDI-DrugBank.d171.s0
|
DDI-DrugBank.d171.s0.p2
|
There was a small increase in plasma concentrations of capecitabine and one metabolite (5-DFCR);
|
capecitabine
|
5-DFCR
|
NONE
|
Capecitabine_ddi.xml
|
DDI-DrugBank.d88.s1
|
DDI-DrugBank.d88.s1.p0
|
The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
|
fentanyl
|
ritonavir
|
MECHANISM
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s2
|
DDI-DrugBank.d170.s2.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
nalidixic acid
|
pyrazolones
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1240
|
- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
|
Indocin
|
Anaprox
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s2
|
DDI-DrugBank.d521.s2.p269
|
Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol
|
Tricyclic antidepressants
|
tramadol
|
EFFECT
|
Cyclobenzaprine_ddi.xml
|
DDI-DrugBank.d150.s3
|
DDI-DrugBank.d150.s3.p0
|
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
|
cyclosporine
|
pimozide
|
NONE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s15
|
DDI-DrugBank.d48.s15.p47
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Dilantin
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p6
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
quinidine
|
quinine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1407
|
Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.
|
tricyclic antidepressants
|
cimetidine
|
MECHANISM
|
Amitriptyline_ddi.xml
|
DDI-DrugBank.d99.s24
|
DDI-DrugBank.d99.s24.p3
|
Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
|
Anticonvulsants
|
progestins
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s12
|
DDI-DrugBank.d485.s12.p6
|
This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
|
NSAIDs
|
ACE inhibitors
|
ADVISE
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s8
|
DDI-DrugBank.d334.s8.p0
|
Although verapamil administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by bombesin or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis.
|
verapamil
|
bombesin
|
NONE
|
11125235.xml
|
DDI-MedLine.d133.s4
|
DDI-MedLine.d133.s4.p0
|
Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.
|
macrolide antibiotics
|
corticosteroids
|
MECHANISM
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s19
|
DDI-DrugBank.d314.s19.p4
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.